ADARx aims for $318 million IPO as TRexBio and Retension also file

ADARx Pharmaceuticals, a siRNA biotech currently in Phase 3 trials, announced plans to raise roughly $318 million through an initial public offering.

The company is joining other biotech firms such as TRexBio and Retension, which have recently entered the IPO filing queue, indicating a resurgence of biotech listings in the fall market.

The proposed offering reflects ADARx's strong funding position and its intent to leverage public markets to support late-stage development, though details on pricing and timing remain pending.